LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
INSIDE INDUSTRY For e-subscribers (PDF)
Vol 21, No 04, April 2017
ATOZET® a New Combination Treatment Option for High-Risk Patients to Lower LDL Cholesterol, is Now Approved in Singapore

MSD (known as Merck in the US and Canada) announced on Feb 28 the approval of ATOZET (ezetimibe and atorvastatin) in Singapore by the Health Sciences Authority (HSA). The approval helps to address an urgent medical need as a recent Dyslipidemia International Study (DYSIS) revealed more than 70 per cent of patients from thirty countries worldwide (across Europe, the Middle East, Canada, Africa and...

ASEAN+ Rare Disease Network Established

SINGAPORE, 22 March 2017 — The first ASEAN+ Rare Disease Network has been established, bringing together patient support groups from across Southeast Asia (Singapore, Malaysia, Indonesia, the Philippines and Vietnam) and Hong Kong. The mission of this Network is to better understand the needs of rare disease patients and their caregivers in the region, in order to identify areas for improvement...

Luye Medical Joins Forces with OncoCare To Expand Its Integrated Healthcare Services Platform for Their Patients

Singapore-based Luye Medical Group has entered into a strategic partnership with OncoCare Cancer Centre furthering its ongoing strategy to make private healthcare services more integrated and available. OncoCare is the second largest private oncology treatment center in Singapore with strong growth in the last few years. With new equity investment from Luye Medical, the integrated oncology specialists...

NUS Pharmacy Team Develops Online "Calculator" to Predict Risk of Early Hospital Readmission

Patients who are discharged after a hospital stay will want to stay away from the hospital for as long as possible. However, in Singapore, approximately 15 per cent of patients who have been discharged from hospitals will succumb to a readmission within 30 days, while globally, readmission rates within 30 days can be as high as 20 per cent. The good news is, studies have shown that readmissions within 15 days...

The Bare Essentials: Ensuring Affordable Access to Insulin

The cost and availability of insulin is a growing concern and an issue of worldwide importance. The skyrocketing list prices of insulin-along with those of certain other drugs and medical products-in the USA became a major political issue last year. More recently, in January, 2017, a lawsuit was filed in a federal court in Massachusetts alleging that the three pharmaceutical companies that control the...

AstraZeneca's CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Death and Hospitalisations for Heart Failure Versus Other Type-2 Diabetes Medicines

AstraZeneca announced results of the first large real-world evidence study of its kind evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving treatment with a newer class of diabetes medicines, SGLT-2 inhibitors (SGLT-2i). [1] The CVD-REAL study assessed data from more than 300,000 patients across six countries, 87% of whom did not...

news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
Asia Pacific Biotech News
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health in the 21st century - Trust your guts
Dental health - The root to good health
Cancer - Therapies and strategies for better patient outcomes
Water management / Vaccination
Regenerative medicine / Biotech start ups
Digital healthcare / 3D printing
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy